Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Short Interest Up 121.9% in April

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 7,100 shares, a growth of 121.9% from the March 31st total of 3,200 shares. Based on an average trading volume of 7,300 shares, the short-interest ratio is presently 1.0 days.

Institutional Trading of Calliditas Therapeutics AB (publ)

An institutional investor recently bought a new position in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. bought a new stake in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 980 shares of the company’s stock, valued at approximately $25,000. Institutional investors own 2.83% of the company’s stock.

Calliditas Therapeutics AB (publ) Price Performance

Shares of NASDAQ CALT traded up $0.05 during midday trading on Friday, reaching $19.50. 3,791 shares of the company were exchanged, compared to its average volume of 7,766. The company has a quick ratio of 3.08, a current ratio of 3.13 and a debt-to-equity ratio of 2.89. Calliditas Therapeutics AB has a one year low of $15.25 and a one year high of $29.30. The stock has a market cap of $580.92 million, a P/E ratio of -11.89 and a beta of 1.50. The stock’s 50-day moving average price is $20.86 and its 200-day moving average price is $20.61.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last issued its quarterly earnings data on Wednesday, February 21st. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.02. Calliditas Therapeutics AB (publ) had a negative net margin of 38.72% and a negative return on equity of 104.47%. The company had revenue of $42.45 million for the quarter, compared to analysts’ expectations of $36.24 million. During the same quarter in the previous year, the firm posted ($0.01) earnings per share. On average, sell-side analysts anticipate that Calliditas Therapeutics AB will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, February 22nd.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.